

Table 1. Disproportional methods in prostaglandins analogs

Drug	SOC	PT	PRR	CI -	CI +	ROR	CI -	CI +	IC	IC025	Chi Square	p Value
TRAVOPROST	Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)	Malignant Mediastinal Neoplasm	3046.8	2002.1	4636.8	3064.4	2010.9	4669.9	10.7	10.3	66121.7	< 0.00001
TRAVOPROST	Investigations	Blood Immunoglobulin E Increased	76.9	56.3	105.1	77.4	56.5	105.9	6.2	6.1	2944.0	< 0.00001
LATANOPROST	Eye Disorders	Cataract	25.2	23.7	26.8	26.3	24.7	28.0	4.6	4.6	22483.7	< 0.00001
BIMATOPROST	Eye Disorders	Blepharospasm	20.3	15.7	26.2	20.4	15.8	26.3	4.3	4.3	1084.5	< 0.00001
TRAVOPROST	Ear And Labyrinth Disorders	Hypoacusis	8.8	7.1	10.8	8.9	7.2	11.0	3.1	3.1	591.6	< 0.00001
TRAVOPROST	Investigations	Full Blood Count Abnormal	7.0	5.1	9.6	7.1	5.1	9.7	2.8	2.7	201.0	< 0.00001
LATANOPROST	Ear And Labyrinth Disorders	Hypoacusis	6.1	5.3	7.0	6.1	5.3	7.0	2.6	2.6	807.4	< 0.00001
TAFLUPROST	Skin And Subcutaneous Tissue Disorders	Skin Exfoliation	3.4	2.1	5.6	3.4	2.1	5.7	1.8	1.7	25.5	< 0.00001
TRAVOPROST	Metabolism And Nutrition Disorders	Diabetes Mellitus	2.4	1.8	3.3	2.5	1.8	3.3	1.3	1.3	38.7	< 0.00001
LATANOPROST	Metabolism And Nutrition Disorders	Diabetes Mellitus	2.1	1.7	2.4	2.1	1.7	2.5	1.0	1.0	46.4	< 0.00001
TAFLUPROST	General Disorders And Administration Site Conditions	Chest Discomfort	2.1	1.2	3.6	2.1	1.2	3.6	1.0	1.0	6.5	0.010844
TAFLUPROST	Gastrointestinal Disorders	Dry Mouth	2.0	1.1	3.6	2.0	1.1	3.6	1.0	0.9	5.6	0.017948

PRR, Proportional Reporting Ratio. ROR, Reporting Odds Ratio. BCPNN, Bayesian Confidence Propagation Neural Network. IC025, Information Component 0.25. CI, Confidence Intervals.